Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma
Autor: | Evan Popoff, Michael L. Andria, Yingxin Xu, Sam Keeping, Chrysalyne D. Schmults, Amarnath Challapalli, Gerasimos Konidaris, Chieh-I Chen, Matthew G. Fury, Andreas Kuznik, Kanwarjit Singh, Rachel Allen, Thi-Minh-Thao Huynh, Morganna Freeman, Medha Sasane, Eggert Stockfleth, Dieter Ayers, Ali Mojebi, Shannon Cope |
---|---|
Rok vydání: | 2020 |
Předmět: |
Oncology
Cancer Research medicine.medical_specialty Cutaneous squamous cell carcinoma Skin Neoplasms medicine.medical_treatment Programmed Cell Death 1 Receptor Cetuximab Pembrolizumab Antibodies Monoclonal Humanized Carboplatin 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Indirect Treatment Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Overall survival Humans Immune Checkpoint Inhibitors EGFR inhibitors Chemotherapy Clinical Trials as Topic business.industry Programmed Cell Death Protein 1 Inhibitor Hazard ratio General Medicine Progression-Free Survival ErbB Receptors Observational Studies as Topic 030220 oncology & carcinogenesis Carcinoma Squamous Cell Cisplatin business |
Zdroj: | Future oncology (London, England). 17(5) |
ISSN: | 1744-8301 |
Popis: | Aim: To estimate the comparative efficacy of cemiplimab, a programmed cell death protein 1 inhibitor, versus EGFR inhibitors, pembrolizumab and platinum-based chemotherapy in terms of overall survival (OS) and progression-free survival. Patients & methods: We performed an indirect treatment comparison of cemiplimab and other available systemic therapies for patients with advanced cutaneous squamous cell carcinoma. Results: Cemiplimab was associated with benefits in OS (hazard ratios range: 0.07–0.52) and progression-free survival (hazard ratios range: 0.30–0.67) versus EGFR inhibitors and pembrolizumab (data from KEYNOTE-629). Cemiplimab was more efficacious versus platinum-based chemotherapy in terms of OS. Conclusion: Cemiplimab may offer improvements in survival for advanced cutaneous squamous cell carcinoma patients compared with existing systemic therapies. |
Databáze: | OpenAIRE |
Externí odkaz: |